الصفحة الرئيسية>>Signaling Pathways>> Others>>BRM/BRG1 ATP Inhibitor-1

BRM/BRG1 ATP Inhibitor-1 (Synonyms: Brahma Homologue/Brahma-related Gene 1 Adenosine 5'-triphosphate Inhibitor 1)

رقم الكتالوجGC34891

BRM / BRG1 ATP Inhibitor-1 (المركب 14) هو متماثل خيفي مزدوج نشط عن طريق الفم (BRM) / SWI / SNF مرتبط بمصفوفة معتمدة على الأكتين لعائلة الكروماتين الفرعية عضو 2 (SMARCA2) والجين 1 المرتبط ببراهما (BRG1) / مثبط نشاط SMARCA4 ATPase ، كلا من IC50s أقل من 0.005 ميكرومترBRM / BRG1 ATP Inhibitor-1 له نشاط مضاد للسرطان

Products are for research use only. Not for human use. We do not sell to patients.

BRM/BRG1 ATP Inhibitor-1 التركيب الكيميائي

Cas No.: 2270879-17-7

الحجم السعر المخزون الكميّة
1mg
405٫00
متوفر
5mg
729٫00
متوفر
10mg
1170٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM[1]. IC50: ﹤0.005 µM (BRM, BRG1)[1]

Reference:
[1]. Papillon JPN, et al. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers. J Med Chem. 2018 Nov 21;61(22):10155-10172

مراجعات

Review for BRM/BRG1 ATP Inhibitor-1

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRM/BRG1 ATP Inhibitor-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.